White Bagging vs Brown Bagging in Infusion Therapy
Payers shift specialty drugs to pharmacies to capture rebates and bypass practice margins.
Specialty drugs now represent roughly half of total drug spending for commercial health plans, used by a fraction of covered patients. That concentration of cost sits on the medical benefit, where providers bill and payers have historically had the least pricing leverage. Buy-and-bill became the obvious target.
AHIP has cited data suggesting hospitals charge more than twice what specialty pharmacies pay for the same products. Payers are using that framing to justify policy.
The mechanism is a benefit shift. Move a drug from the medical benefit to the pharmacy benefit, and the plan gains different negotiating tools, access to rebate structures that don't exist on the medical side, and the ability to route fulfillment through contracted pharmacy partners. Commercial plans reported receiving rebates on a substantial portion of provider-administered drugs billed under the medical benefit in 2023; that figure should be verified against current CMS or AHIP published data. That rebate economy gives payers a second financial reason to prefer pharmacy-side fulfillment, independent of any acquisition cost argument.
Aetna's July 2025 move makes the dynamic concrete. The company shifted five provider-administered drugs, including Ocrevus, Remicade, and Xolair, from the medical to the pharmacy benefit. The margin that previously flowed to infusion centers and physician practices now routes to CVS-affiliated specialty pharmacies. Aetna is owned by CVS. The vertical integration shapes the policy, and practices cannot respond to it effectively until they understand it in those terms.
What Buy-and-Bill Actually Earns, and for Whom
Under Medicare Part B, reimbursement follows ASP plus a statutory add-on. After sequestration, the effective rate lands below the nominal figure. Commercial rates are negotiated separately, and the markup over acquisition cost varies considerably by drug, by payer contract, and by the purchasing power of the practice. Any average figure obscures more than it reveals.
The structural outlier is the 340B program. Qualifying safety-net providers acquire drugs at prices well below ASP and earn margin on Medicare and commercial patients alike. Buy-and-bill at 340B is the most profitable version of this model, and it is available only to a defined class of eligible entities. For independent and non-340B practices, however, the economics often invert: buying above ASP produces negative margins on Medicare patients and thin ones on commercial.
Here is what payer-side analyses consistently underweight. Drug margin is not pure profit extracted from a billing line. Instead, it subsidizes the actual cost of receiving, storing, mixing, and tracking specialty drugs, many of which require cold chain management, limited-use windows, and detailed lot tracking. Those costs do not disappear when the delivery model changes. They become uncompensated.
For many independent infusion and oncology practices, drug margin is the load-bearing wall holding the rest of the operation upright. It funds staffing, clinical infrastructure, and the overhead that administration fees alone cannot support. This is why mandatory bagging policies are destabilizing in ways that extend well beyond a revenue line item: losing that margin removes the subsidy that was covering other operational costs.
How White Bagging Reshapes the Practice's Revenue and Operational Load Simultaneously
The revenue impact of white bagging is straightforward: the practice loses drug acquisition margin and bills administration codes only. The claim shrinks to a fraction of what it was under buy-and-bill. What rarely gets acknowledged is that the operational burden does not shrink with it.
Under white bagging, a specialty pharmacy dispenses the drug and ships it to the infusion site. The pharmacy bills the drug under the pharmacy benefit. The practice bills only for administration under the medical benefit. However, the practice still receives the shipment, verifies contents, confirms temperature compliance during transport, stores the product appropriately, and maintains segregated inventory. White-bagged drugs cannot be mixed with house stock without creating compliance exposure. That segregation is a compliance requirement.
Short notice windows compound the difficulty. When a payer adds a drug to its white bagging list, practices typically receive 30 to 60 days to reconfigure workflows, retrain staff, establish storage protocols, and update inventory tracking systems. Reimbursement for that transition is generally not provided, though practices should confirm the terms of their specific payer contracts.
Waste and dose-adjustment risk are where things get genuinely complicated, particularly in oncology. Dosing is frequently weight-based or adjusted according to lab values available on the day of the visit. A drug dispensed days earlier to prior specifications will not match what the clinician determines is appropriate that morning. Waste handling under white bagging arrangements varies by payer contract; practices should confirm in writing which party bears the cost of a wasted vial and what documentation requirements apply.
Roughly half of hospitals have policies that restrict or prohibit white bagging, according to findings published by the American Hospital Association. Provider-side resistance is real and widespread. Buy-and-bill remains the dominant channel in oncology by volume. However, the direction of payer pressure is clear, and practices that have not yet faced mandatory white bagging requirements from their major commercial payers should assess the likelihood that they will.
Where Brown Bagging Creates Risk That Neither Practice nor Payer Fully Accounts For
Brown bagging is the arrangement where a patient picks up the drug at a home or retail pharmacy, transports it to the infusion site, and the practice administers it. The practice has no involvement in drug acquisition, no billing responsibility for the drug, and no control over anything that happened to the product between the pharmacy counter and the infusion chair.
That chain-of-custody gap is the problem. Specialty drugs are temperature-sensitive, with narrow acceptable ranges. If a patient transports a biologic without maintaining required temperature conditions, the practice that administers it carries clinical and legal exposure it had no ability to prevent. This is the reason most provider organizations, payers, and accrediting bodies have moved away from brown bagging; practices should confirm current guidance from their relevant accrediting body.
The dose-adjustment problem is more acute here than under white bagging. After all, at least under white bagging, a professional pharmacy manages dispensing, verification, and chain-of-custody documentation up to the point of delivery. Under brown bagging, there is a patient, a prescription, and whatever happened in between.
Brown bagging has been largely eliminated from active use in many markets. It still warrants attention because some payer contracts continue to reference it, and practices need to be able to identify and push back on that language during contract review. Treating it as interchangeable with white bagging, or simply not flagging it, is the kind of mistake whose consequences surface at the worst possible moment.
The Legislative Response and What It Means for Practices Navigating Mandates Today
As of mid-2025, approximately a dozen states have enacted bans on mandatory white and brown bagging policies, with additional states carrying active legislation. Practices should verify current legislative status in their state through their state medical association or legal counsel, as this area changes frequently. A practice's actual exposure to payer-mandated bagging depends heavily on where it operates.
Legislative approaches vary. Some states prohibit mandatory bagging outright. Others require that the treating clinician retain authority to determine appropriateness case by case, instead of allowing a blanket payer mandate to override clinical judgment. Arkansas, Minnesota, and Tennessee have enacted provisions addressing payer requirements related to site of care for clinician-administered drugs; practices in those states should review the specific statutory language with counsel.
The AMA, ASCO, and other professional organizations have taken formal positions opposing mandatory bagging and have been active in advocacy efforts at the state level.
There is a patient cost dimension here that practices should communicate clearly. Moving a drug from the medical to the pharmacy benefit may expose the patient to a separate deductible and different out-of-pocket costs under the pharmacy benefit structure. The specific impact depends on the patient's plan design. That is simultaneously a patient retention issue, a communication issue, and a clinical necessity documentation issue. Practices that help patients understand what is happening are better positioned across all three.
Legislative status in this area changes quickly. So, assumptions based on last year's policy are unreliable guides to what a payer can mandate in your state today.
How the Billing Workflow and Denial Risk Differ Across the Three Models
Buy-and-bill billing is technically demanding. J-code accuracy, ASP documentation, route of administration, infusion duration, units, and applicable modifiers must all be correct at the claim level, and each one is its own denial vector. ASP compliance is not static: CMS continues refining its auditing processes, and discrepancies between acquisition cost records and billed amounts create retrospective adjustment exposure. Acquisition price records must be maintained with the same rigor as billing records, continuously, not only when an audit notice arrives.
White bagging billing is narrower in scope but introduces a distinct failure category. The practice bills only administration codes, but benefit coordination errors, specifically billing the drug to the wrong benefit or failing to coordinate with the specialty pharmacy's drug claim, are a denial type that simply does not exist under buy-and-bill. Practices that are not actively monitoring for this gap will discover the failures only after they are already deep in the denial queue.
Prior authorization creates different risk profiles under each model. Under buy-and-bill, the PA must cover both drug and administration, tied to the practice's NPI and the specific drug it will dispense. Authorization lapses on recurring infusion schedules are among the more common denial drivers in this model. Under white bagging, the specialty pharmacy handles PA for the drug while the practice handles PA for administration, and neither entity has full visibility into the other's authorization status. That blind spot generates coordination failures at the handoff. A pharmacy-side PA delay means a drug arrives at the practice before authorization is confirmed, and the practice faces a waste-or-wait decision with real financial stakes.
Denial rates across the infusion billing landscape have increased in recent years, concentrating in authorization gaps, eligibility errors, and documentation deficiencies; practices should benchmark their own denial rates against current industry data from sources such as MGMA or their billing system reporting. Each delivery model shifts where the failure is most likely to occur, and a denial management strategy that does not account for that distinction will consistently miss the right problems.
Underpayment is a persistent secondary issue under buy-and-bill. Line-level reconciliation against contracted rates and ASP is necessary to catch short payments. Remittance review that stops at claim-level totals misses drug-specific underpayments that become permanent write-offs if not caught and appealed promptly.
What Practices Can Do to Protect Revenue Regardless of Which Model Their Payers Impose
The starting point is mapping. Which payers mandate white bagging, for which drugs, under which benefit category? That payer-by-model-by-drug inventory determines where your billing workflows and authorization processes need to operate differently, not just more carefully. Without it, you are managing exceptions reactively.
Under buy-and-bill, revenue cycle control begins before the claim is generated. Authorization must be confirmed and current before the drug is ordered. A lapse on a high-cost biologic is a cash-flow emergency, not a paperwork error you fix in the rework queue. J-code and unit accuracy at charge capture prevents the most common denial types; errors introduced at this stage cannot be corrected cheaply downstream.
Under white bagging, the coordination layer is where revenue is most at risk. Clear accountability between the practice and the specialty pharmacy, specifically who owns PA for the drug versus PA for administration, is a revenue protection requirement. Gaps in that handoff generate denials that neither party catches quickly because each sees only its portion of the authorization picture. Even where the labor of handling white-bagged drugs cannot be billed, it should be documented; it belongs in payer contract negotiations and in site-of-care routing decisions.
Denial management must be model-specific. A white bagging authorization coordination failure requires a different root cause analysis and a different corrective workflow than a buy-and-bill J-code error or an ASP documentation gap. Practices that group all infusion denials into a generic queue are burying the signal they need to fix the right problems.
General-purpose RCM tools are designed for claim volume and standard billing workflows. They are not built for the authorization lifecycle complexity of recurring infusion treatments, the ASP compliance demands of buy-and-bill, or the benefit-coordination requirements of white bagging. So, practices operating across multiple delivery models simultaneously need infrastructure that can handle all three distinctly. Ruby is an infusion-specialized RCM platform that covers benefits verification, prior authorization, J-code billing, denial management, and accounts receivable for practices navigating buy-and-bill and white bagging payer policies at the same time.
